Navigation Links
Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
Date:8/31/2009

NEW YORK, Aug. 31 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present an overview of the Company's lead drug candidates, KRX-0401 (perifosine) and Zerenex(TM), at the upcoming Rodman & Renshaw Annual Global Investment Conference in New York City. Mr. Bentsur's presentation will take place on Wednesday, September 9th at 2:50 pm ET at the New York Palace Hotel (Spellman Salon, 5th Floor) and will be audio webcast live, accessible from the Investor Information page of the Company's website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

Additionally, Keryx Biopharmaceuticals, Inc. today announced that it will host an Investor/Analyst Day on Tuesday, September 22nd in New York City beginning at 5:30 pm ET, by invitation only. Scheduled speakers include:

Discussing Perifosine Phase 3 SPA in Multiple Myeloma:

Kenneth C. Anderson, M.D.

  • Director, Jerome Lipper Multiple Myeloma Center and Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute.
  • Dr. Anderson's team at Dana-Farber Cancer Institute led clinical trials in multiple myeloma of the novel proteasome inhibitor Velcade(R), as well as the immunomodulatory drug Revlimid(R).

Discussing Perifosine Phase 2 Results in Colon Cancer:

Johanna Bendell, M.D.

  • Director, GI Oncology Research and Assoc. Director, Drug Development Unit, Sarah Cannon Research Institute.
  • Dr. Bendell has served as an invest
    '/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
2. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
3. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
4. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
9. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 IQ Formulations ... today announced its continued support of the Cystic Fibrosis ... participated in a fundraising campaign led by TigerFitness.com in ... IQ Formulations’ sales were donated to the respected nonprofit ... a TigerFitness.com fundraiser to support Isla, a young girl ...
(Date:8/27/2014)... Aspirus Wausau Hospital today announced the first extensive ... O.R. at Aspirus Wausau Hospital, in Wausau, WI. ... will be Buzz, a centralized surgical hub for operating ... navigation, imaging and communications connectivity. , Buzz Digital ... hardware all controlled from the full HD 42” multi-touch ...
(Date:8/27/2014)... 27, 2014 SCOTT Sports is ... Utah’s first indoor mountain bike and BMX park. SCOTT ... bikes in both adult and youth sizes for the park’s ... a distribution warehouse in Ogden, Utah, recently moved its U.S. ... “We are proud to be a partner with the Wasatch ...
(Date:8/27/2014)... By Steven Reinberg ... -- A hormone used to reduce the need for blood ... new study suggests. Synthetic erythropoietin (EPO), which stimulates red ... shortly after preterm birth, said lead researcher Dr. Petra Huppi, ... of Geneva, in Switzerland. "The real test of whether ...
(Date:8/27/2014)... CIC microGUNE, the Co-operative Research Centre into ... seeks to generate innovative solutions based on ... mobility industry and life sciences, among others. ... Tecnun are collaborating with CIC microGUNE on ... funded by the Etortek 2013-2014 programme of ...
Breaking Medicine News(10 mins):Health News:IQ Formulations Contributes Sizeable Donation to Cystic Fibrosis Foundation 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3Health News:Microtechnologies for driving forward mobility and human health 2
... hearing damage from acoustic shock, say health experts. // , ... functioning of the ear or of the nervous system, which ... earphone by a sudden sharp rise in the acoustic pressure ... a bleep or any unexpected noise. Two thirds of call ...
... For patients on hemodialysis, the use of dialysis filters ... approach to the common problem of anemia, reports a ... 39th Annual Meeting and Scientific Exposition in San Diego. ... Hospital in Vicenza, Italy, analyzed the outcomes of 172 ...
... acquired respiratory syndrome (SARS), has been responsible for around ... Researchers from Brookhaven’s biology department and the National Synchrotron ... controlling the virus . They have successfully identified a ... new anti-SARS virus drugs.The stage has been set now ...
... bypass surgery for morbid obesity have increased risk factors ... paper being presented at the American Society of Nephrology's ... ,'Gastric bypass surgery appears to lead to changes ... the formation of kidney stones,' comments Dr. Rajiv Kumar ...
... of clear information about the risks of nanotechnology in ... this powerful potential according //to 14 top international scientists ... issue of the journal Nature. The paper, 'Safe Handling ... nanotechnology risk that must be met if the technology ...
... China for stem cell treatment died on Thursday night in ... ,Willie Terpstra, a New Zealander, was diagnosed with motor ... months ago to have a foetal cell tansplantation operation in ... of voluntary muscle activity that aids speaking, breathing and swallowing. ...
Cached Medicine News:Health News:Vitamin E-Coated Dialysis Filters Help Fight Anemia in Hemodialysis Patients 2Health News:Scientists Close To Identifying Anti-viral Drug for SARS 2Health News:Scientists Close To Identifying Anti-viral Drug for SARS 3Health News:Gastric Bypass Surgery May Lead to Increased Kidney Stone Risk 2Health News:Fear of Possible Harm Hinder Nanotech Development 2
(Date:8/27/2014)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global ... participating in the Morgan Stanley 2014 Global Healthcare Conference ... New York , on Tuesday, September 9, 2014.  ... will be presenting at 9:10 a.m. Eastern Time.  ... join Mr. Dvorak for the Q&A session. ...
(Date:8/27/2014)... -- Sinovac Biotech Ltd. (NASDAQ: SVA ), a leading ... announced the results of the Company,s 2014 Annual General Meeting of ... , PRC. The required quorum, a majority of the common ... shareholders approved the following proposals:  , The re-election of ... Anderson , Kenneth Lee and Meng Mei ...
(Date:8/27/2014)...  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... be participating at the FBR Healthcare One on One ... Conference.  Details of the two events are as follows: ... Wednesday September 3 rd Location: Four Seasons, ...
Breaking Medicine Technology:Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 3
... April 18, 2011 Qmed.com, a UBM Canon ... informative video clips of products and services available ... Vault . Qmed is a free online search ... access to pre-qualified medical device suppliers. ...
... 18, 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... March 31, 2011 on Wednesday, April 27, 2011, after the ... executive officer, will host a conference call to review the ... Time (PT). The press release and a ...
Cached Medicine Technology:Qmed Video Vault Showcases Innovative New Products and Services Available to Medical Device Manufacturers 2Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets 2
... 6 is an enzyme immunoassay (EIA) test ... various specific nuclear antigens (SS-A, SS-B, RNP/Sm, ... is used as an aid in the ... connective tissue disease (MCTD), Sjgren's syndrome and ...
The Invacare Pulse Oximeter provides fast, reliable SpO2 and pulse-rate measurements on any patient from infant to adult. It's designed for simple, accurate spot-checking and is a member of a full-li...
Rad-5v signal extraction pulse oximeter™...
... WristOx® 3100 is a small, ... be worn comfortably on the ... daily activities and for overnight ... the WristOx is intended to ...
Medicine Products: